Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. - Test2 - elhamkhani - TriplyDB

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

http://www.wikidata.org/entity/Q27851702

about

Update in lung cancer and mesothelioma 2012 Clinical use of crizotinib for the treatment of non-small cell lung cancer Crizotinib resistance: implications for therapeutic strategies The role of the ALK receptor in cancer biology Precision medicine in NSCLC and pathology: how does ALK fit in the pathway?Targeted therapies and immunotherapy in non-small-cell lung cancer Tackling ALK in non-small cell lung cancer: the role of novel inhibitors Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs ALK inhibitors in non-small cell lung cancer: the latest evidence and developments Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer The distinctive nature of adenocarcinoma of the lung Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets ALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment options Predictive biomarkers in precision medicine and drug development against lung cancer Combating acquired resistance to tyrosine kinase inhibitors in lung cancer Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Targeting cancer with kinase inhibitors Targeting EML4-ALK driven non-small cell lung cancer (NSCLC)Targeted therapies in CLL: mechanisms of resistance and strategies for management Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies Review of the current targeted therapies for non-small-cell lung cancer Targeted therapies in development for non-small cell lung cancer CIViC database Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1 The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer Molecular pathology of non-small cell lung cancer: a practical guide.Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.Ceritinib in ALK-rearranged non-small-cell lung cancer.

P2860

2fe1cd52661f8e49aa97f2e1aee0bbeeb1e1d6c8 412ff606dcb493c6dd0b06523d65c7d5e878c196

P248

Q24619675-00B59C95-BBD5-4E10-8AE1-D75C608A9F18 Q24630466-C9536B24-C81D-47F1-A22D-8C0DBA6E0AF6 Q26738381-E44AB44F-A083-4F08-9310-7A7185A1DF83 Q26738384-17648E70-A5D6-4192-ADA6-31778DAC7555 Q26738390-F320B55A-0758-4BF1-A97E-C7F310B47E19 Q26738986-3640409E-E933-4CE7-9464-6D005F90CE8E Q26740329-CDB60E44-31C7-4277-BECB-C52B648F5657 Q26741318-8A5E3596-9ABA-46A5-8026-838CC5CC6008 Q26741814-05839D6D-515E-4D3B-8AA8-011F1FCF710C Q26745427-8D8ED77F-7104-4CCC-8CEE-C2605AFB8575 Q26746230-49D11328-B548-42AC-95F6-6023C3697A4C Q26747276-A70D7335-AF63-4F7F-908F-F87D362589BA Q26769659-3D789F49-56A4-43AF-B780-28A587A4AF27 Q26769879-DE18B4C8-77F1-40CE-90E8-97435B0D7F65 Q26774625-87828DF2-A7E5-47CE-AC2D-8857786FB4AB Q26775347-7941E50F-1494-439E-A463-7600F8A6D637 Q26775817-B0F846AF-87FC-4A75-AF85-2C286A317D63 Q26778500-1477178B-CFC3-4448-9CAC-3E4E17F20D07 Q26781159-EDB4CD85-A8B6-4FFB-BDA4-F2C8BA6EF5CD Q26784298-97CADD88-4538-4503-A143-3441FAE40255 Q26795555-0675BF5B-2DBC-4684-BC80-BB860B5A01A8 Q26795556-6D095094-C9A7-46E7-AC61-5006654BCB2B Q26795735-126E560D-F8E5-47C5-A2CF-FE478D806F50 Q26820845-3967DA6F-FA0B-45DD-85D8-7476B36A9EFC Q26824536-1E726CA7-F8D4-4B79-AE6D-DC226400A197 Q26824877-E4F13453-744B-4475-A499-5CD7904E3373 Q26828860-E5DBD1B7-C6EC-4EA2-B565-B74A5A38CEF6 Q26865765-1468B298-12DF-457B-A413-EE3BB3C2DAD2 Q27002155-4E31D056-9725-498A-BB18-DE085545FAAD Q27002528-D492F560-24A2-4945-9E3E-2931295DC500 Q27004161-82975FA2-D1AD-473E-8E63-A135E6526A7C Q27015079-9EB75EF7-D3F3-4FB1-800B-53B25DE34362 Q27022852-5DC61985-4963-47D1-A2E5-B2591771FE80 Q27612411-95782CA2-7894-4F9F-9328-C3AF40C05B00 Q27678436-BF574E7D-0643-488B-90D9-5B4C1DE6529C Q27682565-FE7C544C-56B1-4699-8B27-5F1D45AFF1F1 Q27690919-AD861C67-EADE-487D-8DBC-E1F9C04E4835 Q27852601-657C5A44-2362-44B3-B920-A8612908AD3F Q27852806-6B0BC43A-8513-4101-9943-828B9BAA2E10 Q27852989-E9D08B16-53DB-457F-B0AF-2B8B81DAE1C9

P2860

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

http://www.wikidata.org/entity/Q27851702

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Mechanisms of resistance to cr ...... ed non-small cell lung cancer.

@ast

Mechanisms of resistance to cr ...... ed non-small cell lung cancer.

@en

Mechanisms of resistance to cr ...... ed non-small cell lung cancer.

@nl

type

label

Mechanisms of resistance to cr ...... ed non-small cell lung cancer.

@ast

Mechanisms of resistance to cr ...... ed non-small cell lung cancer.

@en

Mechanisms of resistance to cr ...... ed non-small cell lung cancer.

@nl

altLabel

Mechanisms of resistance to cr ...... ged non-small cell lung cancer

@en

prefLabel

Mechanisms of resistance to cr ...... ed non-small cell lung cancer.

@ast

Mechanisms of resistance to cr ...... ed non-small cell lung cancer.

@en

Mechanisms of resistance to cr ...... ed non-small cell lung cancer.

@nl

P1433

Q27851702-467C3EBA-5408-45B0-BD54-C7AA653A048A

P1476

Q27851702-72FE48CD-98F7-47E2-855B-568B29EBFE9B

P2093

Q27851702-1941AE41-A0C8-419E-91D0-822EC2CA27A2

Q27851702-24F2F638-90B1-47E1-AC01-FCE58DE2D5E5

Q27851702-3C1E1C5A-3824-408A-AEBD-77E57C747DD0

Q27851702-55585F40-350E-4283-ADFA-B29653ACADD4

Q27851702-72F75FF6-D661-4B15-A250-BEBB6CB71804

Q27851702-7FF67259-BA37-4EA8-974D-231243752EFD

Q27851702-B4F0F617-B209-4D2E-BA9A-E656AFD84A08

Q27851702-BE6FF87E-F550-43F0-8DC5-CBD0B2AF44F9

Q27851702-E3DE2426-FEBC-4669-B1E6-069EF98A6E99

Q27851702-E90475B1-5542-457B-8C3B-5860359CC5B9

P2860

Q27851702-0125D8A8-F1D2-42DD-AB6F-B9CFF3E54BA6

Q27851702-1E245FDD-1323-43A1-BBDA-27BF00B29222

Q27851702-22FABBC7-0D0C-4097-BFC9-8779CD231081

Q27851702-2E4F6BD6-8BCE-43DF-8F6F-C3161FF0A960

Q27851702-394D5B1D-B898-442B-9286-1973B931763E

Q27851702-409E8149-9C4C-4161-8EA4-C0FD08E81A6B

Q27851702-49CF4939-1B7F-41CD-AF0B-8AB2E04D9F6F

Q27851702-4C906591-9878-4DCF-9E10-1AD6782C3B2A

Q27851702-50655ADE-01C7-4DE9-BF85-54A8B134B814

Q27851702-52D818B3-0DA1-4C72-9A1A-213905F56706

P304

Q27851702-EC0BDD0E-BE68-443B-A4AE-47C2C087D0B9

P31

Q27851702-383A37AF-666F-4439-8234-EC5EA42567DD

P3181

Q27851702-9DDC5EC7-D5FF-4558-A617-2B96A6799FBE

P356

Q27851702-AE65965A-7815-45F4-8AEB-56FE5B791177

P407

Q27851702-CAC60195-A21E-48D8-89AE-34870B3AE2EC

P433

Q27851702-9B6A5223-3D12-49D5-A68D-BC81C7253FD0

P478

Q27851702-27C8F090-FC34-4C76-B94E-1D1A8FDEA4CB

P50

Q27851702-AFF66A6C-4971-42F7-AE31-B07C83B02858

P577

Q27851702-3E53FCD3-965A-4497-B8EC-AF625E6370DB

P5875

Q27851702-8B73E079-22B1-422B-96C5-4420AA4B7EA3

P698

Q27851702-F855F82F-A289-4EAE-A3E1-8ACB3475F6E5

P921

Q27851702-03A00193-EEB4-4587-8A7F-7C6B69B4BA26

Q27851702-91A8676B-2644-419A-9A7A-2EAA35487DFD

P932

Q27851702-366CB0B5-D972-43C7-BBB7-FBF3804FAE01

P3181

P356

1078-0432.CCR-11-2906

P1433

Clinical Cancer Research

P1476

Mechanisms of resistance to cr ...... ged non-small cell lung cancer

@en

P2093

Amanda B Pilling

http://www.w3.org/2001/XMLSchema#string

Andrew J Weickhardt

http://www.w3.org/2001/XMLSchema#string

Anh T Le

http://www.w3.org/2001/XMLSchema#string

D Ross Camidge

http://www.w3.org/2001/XMLSchema#string

Dara L Aisner

http://www.w3.org/2001/XMLSchema#string

Derek J Linderman

http://www.w3.org/2001/XMLSchema#string

Kimi L Kondo

http://www.w3.org/2001/XMLSchema#string

Lynn E Heasley

http://www.w3.org/2001/XMLSchema#string

Marileila Varella-Garcia

http://www.w3.org/2001/XMLSchema#string

Robert C Doebele

http://www.w3.org/2001/XMLSchema#string

P2860

EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Somatic mutations affect key pathways in lung adenocarcinoma

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.

P304

1472-1482

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

559990

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/1078-0432.CCR-11-2906

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Tatiana G Kutateladze

P577

2012-01-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221738431

http://www.w3.org/2001/XMLSchema#string

P698

22235099

http://www.w3.org/2001/XMLSchema#string

P921

P932

3311875

http://www.w3.org/2001/XMLSchema#string